What is Thymosin Alpha-1?
Thymosin Alpha-1 is a peptide your thymus naturally produces that helps regulate the immune system, particularly T-cell development. Its synthetic form, thymalfasin (Zadaxin), is one of the most clinically validated peptides in this library — approved in over 30 countries for chronic hepatitis B and C and used as an immune adjuvant in cancer care.
Notably, it is not FDA-approved in the United States, which puts it in an unusual position: strong international evidence, restricted US status.2
Benefits & what it’s studied for
Its strongest evidence; randomized trials showed significantly higher virological response vs control.
Studied as an immune adjuvant, including in oncology and critical-care settings.
Interest in immune resilience and aging, though these uses are less rigorously established than the hepatitis data.
How does Thymosin Alpha-1 work?
Thymosin Alpha-1 modulates immune function largely through Toll-like receptor signaling, supporting T-cell maturation and helping balance immune responses — enhancing defense against infection while helping regulate overactivation.6
Dosing & administration
In its approved indications, thymalfasin is given by subcutaneous injection.7
This is educational, not medical advice. We don’t publish dosing as instructions. Candidacy and dosing are determined by a licensed provider.
Risks, side effects & safety
the most common are mild injection-site reactions and occasional flu-like symptoms reflecting immune activation. The bigger US concern is compounded-product quality and immunogenicity rather than the molecule itself.8
Legality & status
Thymosin Alpha-1 is approved internationally (30+ countries, as Zadaxin) but is NOT FDA-approved in the US, where it was part of the 2023 Category 2 cohort. The international evidence is strong; the US restriction centers on compounding quality and immunogenicity concerns. As always, off Category 2 ≠ 503A-compoundable ≠ FDA-approved — and US status is evolving. Confirm with a licensed provider.4 See the full picture in our legality explainer.
Regulatory status as of June 2026 — reconfirm against the live FDA 503A list before go-live.
Thinking about Thymosin Alpha-1?
Talk to a licensed provider who can tell you if it fits your goals — and build a safe protocol.
Research & references
- 1Thymosin Alpha-1 discovery & structure literature. Link to be finalized. link pending
- 2International approvals (30+ countries, Zadaxin) & US FDA status. Link to be finalized. link pending
- 3Chien RN, et al. — pivotal hepatitis B RCT. Hepatology, 1998; link to be finalized. link pending
- 4FDA 2023 Category 2 list — Thymosin Alpha-1 status; FDA-2025-N-6895. Confirm at publish. link pending
- 5Immune adjuvant / oncology & critical-care literature. Link to be finalized. link pending
- 6Dominari A, et al. 2020 — mechanism (TLR signaling, T-cell maturation). Link to be finalized. link pending
- 7Zadaxin label / hepatitis B dosing regimen. Link to be finalized. link pending
- 8Camerini & Garaci 2015 — safety review; FDA compounding concerns. Link to be finalized. link pending
Reference links are illustrative placeholders — replace with verified PubMed/journal URLs before publishing.
Frequently asked questions
Is Thymosin Alpha-1 FDA-approved?+
No, not in the US. It’s approved in 30+ countries (as Zadaxin) for hepatitis and immune indications, but in the US it was placed in Category 2 in 2023.
What is Thymosin Alpha-1 used for?+
Its strongest evidence is in chronic hepatitis B/C and as an immune adjuvant in cancer care; it’s also of interest for broader immune support.
Is Thymosin Alpha-1 safe?+
the main US concern is compounded-product quality, not the molecule.
Why is it restricted in the US but approved elsewhere?+
Much of its US story is about limited approvals/designations and compounding regulation, not a lack of efficacy data.
How strong is the evidence?+
Unusually strong for a wellness-adjacent peptide — studied in thousands of patients — which is why we grade it Well-studied.